RankAlpha logo
Back to Rankings

JBIO

Jade BiosciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case is that JADE101 delivers credible Phase 1 biomarker and PK data in Q2 2026, enabling a clean transition into IgAN patient studies while JADE201 also enters the clinic on schedule. If Jade executes on both assets, investors may start valuing it as a multi-program autoimmune platform with enough capital to reach several inflection points.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -14.2.
What can break
Early biomarker success in healthy volunteers may not translate into patient efficacy in IgAN or other autoimmune indications.
Momentum
82
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $22.00
Why
Momentum82 · Δ7d -14.2
Value41 · Δ7d +0.1
Sentiment68 · Δ7d +22.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
82
34% active weight
Current posture
7d trendSoftening
Δ7d
-14.2
Δ21d
-16.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
68
33% active weight
Current posture
7d trendImproving
Δ7d
+22.3
Δ21d
+36.8
Why this grade

Composite grade A. Momentum 81.9 / Value 41.1 / Sentiment 68.3

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$876.14M
Beta
0.88
Shares Out
49.31M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.29
Rev YoY
-
EPS YoY
+96.8%
Gross Margin
-
Op Margin
-
Net Debt
-$78.62M
Current Ratio
9.01
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology